期刊
BIOMEDICINES
卷 9, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines9081000
关键词
amyotrophic lateral sclerosis; motor neurons; oxidative stress; NAD(+); antioxidants
资金
- University of Valencia (Spain) [OTR2017-18255INVES, OTR201819337INVES]
- Elysium Health Inc. (USA)
ALS is a degenerative disease with no cure or proven therapy. While some drugs have been approved for treatment, there has been no significant breakthrough in the field.
Charcot first described amyotrophic lateral sclerosis (ALS) between 1865 and 1874 as a sporadic adult disease resulting from the idiopathic progressive degeneration of the motor neuronal system, resulting in rapid, progressive, and generalized muscle weakness and atrophy. There is no cure for ALS and no proven therapy to prevent it or reverse its course. There are two drugs specifically approved for the treatment of ALS, riluzol and edaravone, and many others have already been tested or are following clinical trials. However, at the present moment, we still cannot glimpse a true breakthrough in the treatment of this devastating disease. Nevertheless, our understanding of the pathophysiology of ALS is constantly growing. Based on this background, we know that oxidative stress, alterations in the NAD(+)-dependent metabolism and redox status, and abnormal mitochondrial dynamics and function in the motor neurons are at the core of the problem. Thus, different antioxidant molecules or NAD(+) generators have been proposed for the therapy of ALS. This review analyzes these options not only in light of their use as individual molecules, but with special emphasis on their potential association, and even as part of broader combined multi-therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据